AU2001265154A1 - Method and composition for targeting an adenoviral vector - Google Patents

Method and composition for targeting an adenoviral vector

Info

Publication number
AU2001265154A1
AU2001265154A1 AU2001265154A AU6515401A AU2001265154A1 AU 2001265154 A1 AU2001265154 A1 AU 2001265154A1 AU 2001265154 A AU2001265154 A AU 2001265154A AU 6515401 A AU6515401 A AU 6515401A AU 2001265154 A1 AU2001265154 A1 AU 2001265154A1
Authority
AU
Australia
Prior art keywords
targeting
composition
adenoviral vector
adenoviral
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265154A
Inventor
Douglas E Brough
David Einfeld
Imre Kovesdi
Alena Lizonova
Petrus W Roelvink
Thomas J Wickham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of AU2001265154A1 publication Critical patent/AU2001265154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001265154A 2000-05-31 2001-05-30 Method and composition for targeting an adenoviral vector Abandoned AU2001265154A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20845100P 2000-05-31 2000-05-31
US60/208,451 2000-05-31
US63119100A 2000-08-02 2000-08-02
US09/631,191 2000-08-02
PCT/US2001/017391 WO2001092549A2 (en) 2000-05-31 2001-05-30 Method and composition for targeting an adenoviral vector

Publications (1)

Publication Number Publication Date
AU2001265154A1 true AU2001265154A1 (en) 2001-12-11

Family

ID=26903207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001265154A Abandoned AU2001265154A1 (en) 2000-05-31 2001-05-30 Method and composition for targeting an adenoviral vector

Country Status (5)

Country Link
US (1) US20030099619A1 (en)
EP (1) EP1301612A2 (en)
JP (1) JP2003534806A (en)
AU (1) AU2001265154A1 (en)
WO (1) WO2001092549A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
GB0112652D0 (en) * 2001-05-24 2001-07-18 Inst Of Molecul & Cell Biology Internalisation of virus into cells
JP5213298B2 (en) 2002-05-27 2013-06-19 ホルム，ペル・ゾンネ New use of adenovirus and nucleic acid encoding it
AU2003240281A1 (en) 2002-06-14 2003-12-31 Case Western Reserve University Cell targeting methods and compositions
DE602004032330D1 (en) * 2003-02-17 2011-06-01 Fuso Pharmaceutical Ind NOVEL VIRUS VECTOR
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
WO2004084950A2 (en) * 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
EP1613661B1 (en) * 2003-04-04 2011-06-29 Université de Lausanne Peptabody for cancer treatment
EP1649028B1 (en) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviral vector-based vaccines
FR2860004A1 (en) * 2003-09-18 2005-03-25 Roussy Inst Gustave Adenoviral vector encoding modified capsid protein, useful in gene therapy of e.g. cancer and cystic fibrosis, can infect cells deficient in, or lacking, the common receptor for Coxsackie virus B3 and adenovirus
JP2007511211A (en) 2003-11-14 2007-05-10 ホルム，ペル・ゾンネ New use of adenovirus and nucleic acid encoding it
EP1687032B1 (en) 2003-11-14 2010-02-24 Genvec, Inc. Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
CN1972958B (en) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 Method of using adenoviral vectors to induce an immune response
CN104263703B9 (en) * 2004-05-26 2019-12-17 普西奥克瑟斯医疗有限公司 Chimeric adenoviruses for the treatment of cancer
US7776322B2 (en) * 2004-08-16 2010-08-17 Stefan Kochanek Modified viral vector particles
JP2008511336A (en) * 2004-09-01 2008-04-17 アメリカ合衆国 Methods for using adenoviral vectors with increased immunogenicity in vivo
US7556808B2 (en) 2004-12-16 2009-07-07 Philadelphia Health And Education Corporation Dual inhibitors of HIV-1 gp-120 interactions
EP1929021A2 (en) 2005-08-31 2008-06-11 Genvec, Inc. Adenoviral vector-based malaria vaccines
CA2629163C (en) 2005-11-10 2017-03-21 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
CN101583580B (en) * 2006-06-29 2012-10-31 高晓莲 Make and use of surface molecules of varied densities
WO2008140602A2 (en) * 2006-12-07 2008-11-20 The Govenment Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN
WO2008086386A2 (en) * 2007-01-09 2008-07-17 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2009086516A1 (en) * 2007-12-28 2009-07-09 Kalos Therapeutics, Inc. Anti-proliferative compounds and their use
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
KR101154374B1 (en) * 2009-02-18 2012-07-09 재단법인 아산사회복지재단 Composition Comprising Adeno-Associated Virus Serotype 5 Vector for Targeted Gene Delivery
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
KR20120139672A (en) 2009-11-09 2012-12-27 젠벡, 인코포레이티드 Methods of propagating monkey adenoviral vectors
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
EP2855669B1 (en) 2012-05-29 2018-10-10 GenVec, Inc. Modified serotype 28 adenoviral vectors
JP6576326B2 (en) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ Oncolytic adenovirus composition
HUE035875T2 (en) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
TWI710635B (en) 2014-10-09 2020-11-21 美商珍維克公司 Adenoviral vector encoding human atonal homolog-1 (hath1)
CN107690479B (en) 2015-04-30 2022-02-18 皮斯奥克斯治疗公司 Oncolytic adenovirus encoding B7 protein
MX2018007249A (en) 2015-12-17 2019-05-16 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment.
KR20180112024A (en) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression of therapeutic adenoviruses for minimizing the effects on viral dynamics
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3018427A1 (en) * 2016-03-31 2017-10-05 The European Molecular Biology Laboratory Adenoviral coat protein derived delivery vehicles
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
JP2019536468A (en) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ Synthetic adenovirus targeting tumors and uses thereof
US20210139932A1 (en) * 2017-05-03 2021-05-13 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
SE503225C2 (en) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antibody complex for introduction of virus into mammalian cells
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE4311651A1 (en) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5783386A (en) * 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5958672A (en) * 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5939250A (en) * 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
AU726544B2 (en) * 1995-12-08 2000-11-09 University Of Alabama At Birmingham Research Foundation, The Targeted adenovirus vectors
US5955275A (en) * 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
EP0974668B1 (en) * 1998-07-07 2002-10-02 Transgene S.A. Use of adenoviral E4 reading frames to improve expression of a gene of interest

Also Published As

Publication number Publication date
JP2003534806A (en) 2003-11-25
EP1301612A2 (en) 2003-04-16
US20030099619A1 (en) 2003-05-29
WO2001092549A3 (en) 2003-01-16
WO2001092549A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU2001265154A1 (en) Method and composition for targeting an adenoviral vector
AU2001280968A1 (en) Compositions and methods for directed gene assembly
AU2001292836A1 (en) Endoscopic targeting method and system
AU2001261566A1 (en) Well service composition and method
AU2001271210A1 (en) Method for virtual trading
AU1340000A (en) Novel adenoviral vector and methods for making and using the same
AU2001239947A1 (en) Methods and compositions for regulating adipocytes
AU7068600A (en) Encrypted coupons
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU4806100A (en) P element derived vector and methods for its use
AU2778801A (en) Antisense compositions and methods
AU3420701A (en) Method and apparatus for providing advertisements
AU2001289205A1 (en) System and method for tactical couponing
AU2001271720A1 (en) Methods and compositions for determining gene function
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
AU2002327380A1 (en) Cells and methods for propagating adenoviral vectors
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001279850A1 (en) Method and arrangement for studsystem
AU2001232054A1 (en) Vector
AU2001238485A1 (en) Methods and compositions for gene delivery
AU2001233932A1 (en) Method and composition
AU2001288736A1 (en) Method and composition for enhancing vision
AU2002243285A1 (en) Auxiliary metering apparatus and methods
AU2001261513A1 (en) Composition and method for increasing testosterone levels